NeuroStar and EXOMIND sit in the same tms devices category but take different approaches. NeuroStar (Neuronetics) uses Transcranial Magnetic Stimulation (focused figure-8 coil) while EXOMIND (BTL Industries) uses ExoTMS (patented external TMS with proprietary coil design). Both received FDA clearance (2008 and 2024 respectively) and both are actively sold in the US market. The decision between them is rarely about which is objectively better. It's about which fits your specific practice.
Physicians end up comparing these two devices when they're shopping in the $80,000-$150,000 to $100,000-$200,000 price range and want a category leader. Both devices are commonly recommended by sales reps from competing manufacturers, which means physicians often hear inflated claims about one and dismissive claims about the other. This comparison strips out the marketing and looks at pricing, mechanism, evidence, and practice fit side by side.
Side-by-Side Specifications
NeuroStar
EXOMIND
Manufacturer
Neuronetics
BTL Industries
Technology
Transcranial Magnetic Stimulation (focused figure-8 coil)
ExoTMS (patented external TMS with proprietary coil design)
Price (New)
$80,000-$150,000
$100,000-$200,000
Price (Used)
$40,000-$80,000
Limited secondary market (too new)
Treatment Time
19-37 minutes per session
Under 30 minutes per session
Sessions
36 sessions over 9 weeks (standard protocol)
6 sessions (a fraction of what competitors require)
Per Session
$300-$500 (insurance reimbursable)
TBD (emerging pricing)
Annual Consumables
$2,000-$5,000 (treatment caps)
TBD
Annual Maintenance
$5,000-$10,000
TBD
FDA Cleared
Yes (2008)
Yes (2024)
Technology
NeuroStar
Technology: Transcranial Magnetic Stimulation (focused figure-8 coil). First FDA-cleared TMS system. Largest clinical outcomes registry (over 5M treatments delivered). FDA-cleared for MDD, OCD, and anxious depression.
EXOMIND
Technology: ExoTMS (patented external TMS with proprietary coil design). FDA-cleared for depression in just 6 sessions (vs 20-36 for competitors). Also cleared in Canada/EU for anxiety, OCD, and binge eating.
Strongest in category. 100+ published studies. 5M+ treatment outcomes registry. Multiple FDA clearances backed by large RCTs.
EXOMIND
Emerging. FDA clearance data is available. Full peer-reviewed evidence base still developing.
Treatment Experience
NeuroStar
19-37 minutes per session per session. Recommended protocol: 36 sessions over 9 weeks (standard protocol). Treatment areas: Left dorsolateral prefrontal cortex. Patients typically tolerate this platform well when operated by trained clinicians.
EXOMIND
Under 30 minutes per session per session. Recommended protocol: 6 sessions (a fraction of what competitors require). Treatment areas: Dorsolateral prefrontal cortex. Patient experience varies by operator training and settings.
Practice Fit
NeuroStar
Psychiatrists starting a TMS practice who want the most established platform with the strongest insurance reimbursement track record. Practices that value the largest clinical dataset.
EXOMIND
Psychiatrists or multi-specialty practices already in the BTL ecosystem. Early adopters willing to bet on the 6-session protocol advantage.
Pros and Cons
NeuroStar Pros
First-mover advantage: largest installed base in the US
Insurance reimbursement well-established for NeuroStar
FDA-cleared for MDD, OCD, and anxious depression
NeuroStar Cons
Standard TMS depth (~2cm) vs BrainsWay's deep TMS (~6cm)
36-session standard protocol requires significant patient commitment
Per-treatment cap fees reduce margins at high volume
EXOMIND Pros
Only 6 sessions required (vs 20-36 for NeuroStar/BrainsWay)
BTL's sales and support infrastructure
Potential for anxiety, OCD, binge eating clearances in US
Cross-sell path for existing BTL aesthetic practices
EXOMIND Cons
Brand new to market (2024 FDA clearance)
Limited published clinical evidence vs established competitors
Pricing not yet stabilized
The Verdict
Choose NeuroStar if your practice prioritizes Neuronetics's ecosystem, brand recognition, or specific clinical advantages. Psychiatrists starting a TMS practice who want the most established platform with the strongest insurance reimbursement track record. Practices that value the largest clinical dataset. The pros that matter most: First-mover advantage: largest installed base in the US; 5M+ treatments delivered (largest outcomes registry). The biggest tradeoff to accept: Standard TMS depth (~2cm) vs BrainsWay's deep TMS (~6cm).
Choose EXOMIND if BTL Industries's positioning fits better. Psychiatrists or multi-specialty practices already in the BTL ecosystem. Early adopters willing to bet on the 6-session protocol advantage. The pros that matter most: Only 6 sessions required (vs 20-36 for NeuroStar/BrainsWay); BTL's sales and support infrastructure. The biggest tradeoff to accept: Brand new to market (2024 FDA clearance).
For a practice with limited capital that needs maximum flexibility, used pricing tilts the math. NeuroStar used units run $40,000-$80,000; EXOMIND used units run Limited secondary market (too new). For practices with strong patient flow already, the device that integrates with your existing platforms is usually the right answer even if its standalone specs are slightly weaker. For practices building a category from scratch, brand recognition and patient demand matter more than raw clinical specs. Look at which device patients are already asking for in your market before signing a contract.
Market Leader vs Protocol Disruptor
NeuroStar is the most-installed TMS system in the United States with over 6 million treatments delivered. The installed base means more peer data, more reimbursement precedent, and a larger network of trained operators. When a payer questions medical necessity, NeuroStar's track record carries weight.
EXOMIND's value proposition is the 6-session protocol. In a standard NeuroStar practice, a single chair treats 2-3 patients per day through their 36-session protocols. With EXOMIND's 6-session protocol, the same chair could theoretically cycle through patients 6x faster. Whether that throughput advantage translates to revenue depends entirely on your referral pipeline.
Session Economics
NeuroStar with a 36-session protocol generates $10,800-$16,200 per patient at current Medicare rates. EXOMIND's 6-session protocol generates $1,800-$2,700 per patient. The revenue-per-patient is dramatically lower for EXOMIND, but the revenue-per-chair-hour can be higher if you fill the freed-up slots.
The math works for EXOMIND only if your practice has a deep referral pipeline and can consistently fill treatment slots. A practice doing 3 NeuroStar patients per day generates roughly the same revenue as a practice doing 15-18 EXOMIND patients per day. Most psychiatry practices in mid-sized markets struggle to maintain even 2-3 TMS patients per day.
Bottom line: NeuroStar is the right choice for practices in most markets. EXOMIND is the right choice for high-volume practices in major metros with strong referral networks who can fill the throughput advantage.
Frequently Asked Questions
Which is more expensive, NeuroStar or EXOMIND?
NeuroStar runs $80,000-$150,000 new and $40,000-$80,000 used. EXOMIND runs $100,000-$200,000 new and Limited secondary market (too new) used. Per-session pricing is $300-$500 (insurance reimbursable) for NeuroStar and TBD (emerging pricing) for EXOMIND. Annual operating costs (consumables plus maintenance) typically run 5-15% of purchase price for both devices. The right financial comparison includes total cost of ownership over 5 years, not just sticker price.
Which has better clinical evidence, NeuroStar or EXOMIND?
NeuroStar clinical evidence: Strongest in category. 100+ published studies. 5M+ treatment outcomes registry. Multiple FDA clearances backed by large RCTs. EXOMIND clinical evidence: Emerging. FDA clearance data is available. Full peer-reviewed evidence base still developing. Evidence quality is not about study count alone. Look at sample sizes, blinded evaluators, independence from manufacturer funding, and outcome durability. Older devices in the same category usually have stronger evidence because they've been studied longer.
Is NeuroStar or EXOMIND more popular in psychiatry practices?
Both NeuroStar and EXOMIND are commonly used in psychiatry, neurology practices. Market share in any given category shifts year to year. Neuronetics and BTL Industries both maintain active sales forces in the US. Ask other physicians in your specialty which platform they're using and why. Peer references in your local market matter more than national market share data.
Are there safety concerns with NeuroStar or EXOMIND?
Both devices are FDA cleared and have established safety profiles. NeuroStar has these documented concerns: Standard TMS depth (~2cm) vs BrainsWay's deep TMS (~6cm). EXOMIND has: Brand new to market (2024 FDA clearance). Physicians should monitor FDA MAUDE reports for both devices before purchase. Adverse event trends matter because they signal problems that may not appear in marketing materials. Any device with a sudden spike in MAUDE filings deserves closer scrutiny.
Can I use NeuroStar and EXOMIND in the same practice?
Some practices run both devices, especially when they target different patient segments or treatment areas. The downside is duplicated training, parallel consumable inventories, and potential cannibalization between platforms. The upside is broader marketing claims and the ability to switch patients between platforms if one doesn't deliver expected results. Most practices choose one and commit to mastering it rather than splitting volume.
What's the resale value comparison between NeuroStar and EXOMIND?
Used NeuroStar sells for $40,000-$80,000 on the secondary market. Used EXOMIND sells for Limited secondary market (too new). Resale values depend on age, software version, applicator condition, and remaining warranty. Devices with strong installed bases hold value better. Devices with active safety signals or declining manufacturer financial health depreciate faster. Resale value should be a factor in any device purchase, especially if practice plans might change in 3-5 years.
NeuroStar vs EXOMIND: which is better for psychiatry practices in 2026?
For psychiatry practices specifically in 2026, the choice between NeuroStar and EXOMIND depends on three factors: existing equipment compatibility (does the new device integrate with what you already run), patient mix and treatment volume (high-volume practices typically benefit from NeuroStar's first-mover advantage: largest installed base in the us while lower-volume practices often prefer EXOMIND's only 6 sessions required (vs 20-36 for neurostar/brainsway)), and total cost of ownership over 5 years including consumables and maintenance. Run the side-by-side TCO analysis with realistic patient volume projections before committing to either platform.
NeuroStar vs EXOMIND: 2026 update on features and clinical evidence?
As of April 2026, both NeuroStar and EXOMIND continue commercial availability from Neuronetics and BTL Industries respectively. Recent updates worth tracking: software releases, new applicator launches, expanded FDA labeling indications, and new peer-reviewed clinical evidence publications. Manufacturer financial stability also matters for long-term support and parts availability. Both manufacturers share business updates periodically that inform the long-term outlook for each device.
How do I choose between NeuroStar and EXOMIND for my practice?
Use a structured decision framework: list 5-7 must-have requirements specific to your patient mix and practice economics, score NeuroStar and EXOMIND against each requirement on a 1-5 scale, weight the requirements by importance, then sum the weighted scores. The platform that scores meaningfully higher (10%+ gap) is the right choice. If the scores are within 10%, secondary factors decide: manufacturer relationship, financing terms, training availability, and resale value. Avoid choosing based on feature breadth alone because most devices in this category have similar feature checkboxes. The differentiation is in workflow fit, treatment results, and total cost over 5 years.
Are there better alternatives to NeuroStar or EXOMIND in the tms devices category?
In the tms devices category, NeuroStar and EXOMIND are often the leading platforms but other alternatives may fit specific practice profiles better. Other category options include brainsway-deep-tms, magventure, nexstim. Run a 4-platform shortlist evaluation rather than a 2-platform binary because hidden alternatives sometimes outperform on the metrics that matter most to your specific practice.